Dexcom (NSDQ:DXCM) posted second-quarter results this evening that beat the consensus forecast on Wall Street, and raised its outlook for the rest of the year.
The San Diego–based continuous glucose monitoring (CGM) technology company reported a loss of $10.5 million, or $0.12 per share, on sales of $336.4 million for the three months ended June 30. Sales were up 39% compared with Q2 2018, which saw profits of $30.2 million, or $0.34 per share.
Adjusted to exclude one-time items, earnings per share were $0.08, 8¢ ahead of The Street, where analysts were looking for sales of $304.4 million.
“Dexcom generated another outstanding quarter of growth as physicians and people with diabetes continue to embrace real-time CGM and the demonstrated benefits of Dexcom’s G6 system,” Dexcom CEO Kevin Sayer said in a news release.
Dexcom expects to log a non-GAAP operating margin of roughly 7% this year, versus previous expectations of 6%, and upped its top-line outlook to $1.325 billion to $1.375 billion, compared with $1.25 billion to $1.30 billion previously.
